More precisely, results from the EURTAC trial correlated EGFR mutations in cfDNA with OS, PFS, and treatment response and proved the feasibility of using cfDNA instead of tumor biopsy during treatment with erlotinib [145]. Here, EGFR is linked to neoplasm.